All Oncology News

Suman Kambhampati, MD, discusses available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

The FDA has approved abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gemtuzumab ozogamicin for use in combination with daunorubicin and cytarabine as a frontline treatment for patients aged 15 years and older with previously untreated, de novo CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against approving sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of bosutinib (Bosulif) as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The FDA recently approved a supplemental new drug application for Blue Light Cystoscopy with Cysview for surveillance of bladder cancer. Cysview is currently indicated for use for detection of nonmuscle-invasive bladder cancer.

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Number One Rankings in 10 Key Performance Areas Reinforce McKesson Specialty Health’s Leading Position in the Oncology and Hematology Market

Adjuvant chemotherapy given during and after radiotherapy did not improve 5-year overall survival for patients with high-risk endometrial cancer in the phase III PORTEC-3 trial.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Suresh A. Ramalingam, MD, discusses the exciting findings from the KEYNOTE-189 and IMpower150 immunotherapy trials in patients with non–small cell lung cancer.

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

David Mason, MD, addresses the evolving role of surgery for patients with non–small cell lung cancer.

Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy.

UW Carbone Cancer Center will begin treating adults with a “living drug” that employs their own immune cells to fight a common type of aggressive blood cancer.

Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI.

The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.

Kartik Konduri, MD, shares insight on molecular developments, recently discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of non–small cell lung cancer treatment.

The survival benefit with adjuvant chemotherapy in ER-negative breast cancer patients with isolated locoregional recurrence was sustained in the final analysis of the phase III CALOR trial.

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.

Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.

Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma.

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.